Michael Harrison | Precision Medicine | Best Researcher Award

Michael Harrison | Precision Medicine | Best Researcher Award

Dr. Michael Harrison, UCSF, United States

Dr. Michael Harrison is a pioneering pediatric surgeon and fetal therapy expert. πŸŽ“ He earned his B.A. from Yale (1965) and M.D. from Harvard Medical School (1969), followed by extensive surgical training at Massachusetts General Hospital and fellowships in pediatric surgery. πŸ₯ He joined UCSF in 1978, where he became a Full Professor and founded the Fetal Treatment Center. πŸ‘Ά His groundbreaking work in fetal surgery has earned him numerous accolades, including the Golden Plate Award and presidency of the International Fetal Medicine and Surgery Society. 🌍 Now Professor Emeritus at UCSF, he continues to shape the field of pediatric surgery. ✨

Publication Profile

Scopus

Education

Dr. Michael Harrison πŸŽ“ began his academic journey at Yale University (1961-1965), earning a B.A. before pursuing his M.D. in Medicine at Harvard Medical School (1965-1969) πŸ₯. He completed his surgical residency at Massachusetts General Hospital (1969-1971) and advanced his expertise as a Postdoctoral Fellow in Allergy & Immunology at the National Institute of Allergy and Infectious Disease (1971-1973) 🧬. Returning to Massachusetts General, he served as a Senior Resident (1973-1974) and Chief Resident (1974-1975) πŸ”¬. Further specializing, he completed fellowships in Pediatric Surgery at Rikshospitalet (1975-1976) πŸ‡³πŸ‡΄ and Children’s Hospital of Los Angeles (1976-1978) πŸ‘ΆπŸ©Ί.

Experience

Dr. Michael Harrison πŸ₯ has been a Founding Member of the International Fetal Medicine and Surgery Society (1981-present) πŸ‘Ά and has served as its President at the Annual Meeting (1989, 2006) 🎀. He has contributed as a Committee Member for the Medical Advisory Committee of the American Association of Tissue Banks (1993-present) 🧬 and chaired the Committee on Fetal Therapy at APSA (1994-1996) πŸ₯. A Board Member of the International Society of the Fetus as Patient (1997-present) 🌍, he also consults for the MOMS study (2003-present) 🀰. Since 2010, he has been Vice President of the California Academy of Medicine πŸ“š.

Awards

Dr. Michael Harrison πŸ… has received numerous prestigious honors, including the Golden Plate Award (1982, 1988) πŸ†, the William E. Ladd Medal (2010) πŸ…, and the Lifetime Achievement Award (2011) 🌟 from the International Fetal Medicine and Surgery Society. He was elected to the Institute of Medicine (2009) πŸ“œ and honored with the Denis Browne Gold Medal (2013) 🏡️. As a celebrated lecturer, he has delivered keynote addresses worldwide 🌍, including at the Nobel Minisymposium on Fetal Medicine (1998) 🎀. His groundbreaking contributions in pediatric surgery have earned him global recognition and lasting influence in the field.

Research Focus

Dr. Michael R. Harrison is a pioneering surgeon and researcher in pediatric surgery and fetal therapy πŸ₯πŸ‘Ά. His work focuses on maternal-fetal surgery, particularly for conditions like esophageal atresia and diaphragmatic hernia. He has contributed to the development of magnetic compression anastomosis 🧲 and other innovative minimally invasive surgical devices πŸ”¬. His research advances the treatment of complex congenital disorders and improves outcomes for newborns. With numerous publications, he has significantly impacted pediatric device clinical trials πŸ“Š. Dr. Harrison’s groundbreaking contributions continue to shape the future of pediatric and fetal surgical care 🚼✨.

Publication Top Notes

Pediatric Device Clinical Trials Activity: 1999–2022

Lessons Learned From the First-In-Human Compassionate Use of Connect-EAβ„’ in Ten Patients With Esophageal Atresia

Evaluation of a Magnetic Compression Anastomosis for Jejunoileal Partial Diversion in Rhesus Macaques

Sonographic Predictors of Survival in Fetal Diaphragmatic Hernia

Beyond the gut: spectrum of magnetic surgery devices

The Rearing of Maternal–Fetal Surgery: The Maturation of a Field from Conception to Adulthood

The novel application of an emerging device for salvage of primary repair in high-risk complex esophageal atresia

Esophageal Magnetic Compression Anastomosis in Esophageal Atresia Repair: A PRISMA-Compliant Systematic Review and Comparison with a Novel Approach

An experimental study on long term outcomes after magnetic esophageal compression anastomosis in piglets

Novel device for endoluminal esophageal atresia repair: First-in-human experience

Edwin Posadas | Precision Medicine | Best Researcher Award

Edwin Posadas | Precision Medicine | Best Researcher Award

Dr. Edwin Posadas, Cedars-Sinai Cancer, United States

Dr. Edwin M. Posadas is a distinguished oncologist and urologist specializing in prostate cancer research and treatment. He is a Professor at Cedars-Sinai Medical Center and UCLA, co-Director of the Cancer Therapeutics Program, and Medical Director of the Urologic Oncology Program. A Johns Hopkins graduate, he trained at the NIH and University of Michigan. Dr. Posadas has earned numerous accolades, including Castle Connolly Top Doctor and Sigma Xi Honors. An active researcher, mentor, and leader in oncology, he contributes to multiple scientific committees and journals, shaping the future of cancer care. πŸ“šπŸ”¬βœ¨

Publication Profile

orcid

Education

Dr. Edwin Posadas πŸŽ“ began his academic journey at Johns Hopkins University, earning dual B.E.S. degrees in Biomedical and Chemical Engineering (1993) with summa cum laude honors. His studies focused on biological transport systems and physiological fluid mechanics. He then pursued his M.D. at Johns Hopkins School of Medicine (1998) 🩺, followed by an internship and residency at the University of Michigan Medical Center (2001) πŸ₯. Further specializing, he completed a fellowship in Medical Oncology and Hematology (2005) 🧬 at the National Cancer Institute & National Heart, Lung, and Blood Institute, solidifying his expertise in cancer research and treatment. πŸ”¬πŸ’™

Professional Associations

Dr. Edwin Posadas 🩺 is an esteemed member of numerous professional associations and scholarly societies, reflecting his dedication to oncology, urology, and medical ethics. He joined the American Medical Association (1993) πŸ₯, Association of Philippine Physicians of America (1998) πŸ‡΅πŸ‡­, and American College of Physicians (1998) 🩻, later becoming a Fellow (2010) πŸŽ–οΈ. His contributions extend to the American Society of Clinical Oncology (2001) 🧬, American Association for Cancer Research (2001) πŸ”¬, and European Society of Medical Oncology (2012) 🌍. He also actively participates in cancer research initiatives, including the Cancer Moonshot Program (2016) πŸš€ and the Medical Oncology Association of Southern California (2022) 🌿.

Achievements

Dr. Edwin Posadas 🩺 has built a distinguished career in internal medicine and medical oncology, dedicated to advancing patient care and cancer research. In 2001, he became certified in Internal Medicine πŸ₯, laying the foundation for his expertise in diagnosing and managing complex diseases. His passion for oncology led him to further specialize, earning his Medical Oncology certification in 2019 πŸ§¬πŸŽ—οΈ. With decades of experience, he remains committed to innovative cancer treatments, translational research, and personalized patient care, making significant contributions to the oncology community through clinical practice, research, and professional collaborations. πŸ”¬πŸ’™

Research Focus

Dr. Edwin M. Posadas is a distinguished researcher specializing in prostate cancer πŸ”¬, metastasis 🧬, and nanotechnology-based diagnostics πŸ₯. His work focuses on understanding the molecular determinants of metastasis in prostate cancer, particularly liver and visceral metastases. He has contributed to the development of nanotechnology solutions for early cancer detection 🩸 and circulating tumor cell profiling. His research also explores the role of FYN kinase in cancer growth and motility. With multiple grants from the National Cancer Institute and Congressionally Directed Medical Research Programs, his pioneering work is advancing precision oncology and metastasis prevention in prostate cancer patients. πŸŽ—οΈ

Publication Top Notes